Identification of hypermethylated genes associated with cisplatin resistance in human cancers

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2870-2879

  Chang, Xiaofei ^a   Monitto, Constance L ^a   Demokan, Semra ^a   Kim, Myoung Sook ^a   Chang, Steven S ^a   Zhong, Xiaoli ^a   Califano, Joseph A ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD146 ANTIGEN; CISPLATIN; SMALL INTERFERING RNA;

ARTICLE; C8ORF4 GENE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG RESISTANCE; GENE; GOS2 GENE; HUMAN; HUMAN CELL; LAMB3 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S100P GENE; SAT GENE; TUBB GENE; UPREGULATION;

ALGORITHMS; AZACITIDINE; CALCIUM-BINDING PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; KB CELLS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 77950801864     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3427     Document Type: Article

References (39)

1. Kruh GD. Introduction to resistance to anticancer agents. Oncogene 2003;22:7262-7264
2. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59 Suppl 4:9-17, discussion 37-38
3. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319
4. Li QL, lto K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109: 113-124
5. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35. (Pubitemid 32405812)
6. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692
7. Segura-Paeheco B, Perez-Cardenas E, Taja-Chayeb L, et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med 2006;4:32.
8. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-1538
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354
10. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-574
11. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10: 4420-4426
12. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-495
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspeeific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826
14. Tang H, Liu YJ, Liu M, Li X. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs 2007;18:633-639
15. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17:4059-4069
16. Tsunoda T, Koga H, Yokomizo A, et al. Inositol 1,4,5-trisphosphate (IP3) receptor typel (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 2004;24:1396-1402
17. Allen WL, McLean EG, Boyer J, et al. The role of spermidine/ spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 2007;6:128-137 (Pubitemid 46206675)
18. Marverti G, Giuseppina Monti M, Pegg AE, et al. Spermidine/ spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1, N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis 2005;26: 1677-1686
19. Hector S, Porter CW, Kramer DL, et al. Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1, N11-diethylnorspermine at the level of spermidine/ spermine N1- acetyltransferase. Mol Cancer Ther 2004;3:813-822
20. Marverti G, Piccinini G, Ghiaroni S, et al. N1, N12-bis(ethyl)spermine effect on growth of c/s-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian-carcinoma cell lines. Int J Cancer 1998; 78:33-40.
21. Varma R, Hector S, Greco WR, et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 2007;59:711-723
22. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059-5065
23. Averboukh L, Liang P, Kantoff PW, Pardee AB. Regulation of S100P expression by androgen. Prostate 1996;29:350-355
24. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824
25. Fuentes MK, Nigavekar SS, Arumugam T, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007;50:1230-1240
26. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-2657 (Pubitemid 36605209)
27. Wang G, Platt-Higgins A, Carroll J, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006;66:1199-1207
28. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004;23: 1531-1538
29. Bartling B, Rehbein G, Schmitt WD, et al. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007;43:1935-1943
30. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007;33:101-137
31. Marcu L, Bezak E, Olver I, van Doom T. Tumour resistance to cisplatin: a modelling approach. Phys Med Biol 2005;50:93-102. (Pubitemid 40185403)
32. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 2005;93:302-309
33. Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82: 199-206.
34. Siu WY, Arooz T, Poon RY. Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 1999;250: 131-141
35. Remvikos Y, Mosseri V, Zajdela A, et al. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 1993; 698:193-203.
36. Hietanen P, Blomqvist C, Wasenius VM, et al. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995;71: 1029-1032
37. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007;6:1089-1098
38. Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 2003;63:5909-5916
39. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 2004;91:270-276 (Pubitemid 39037071)